Literature DB >> 11358332

Mutation W284L of the human delta opioid receptor reveals agonist specific receptor conformations for G protein activation.

Y Hosohata1, E V Varga, D Stropova, X Li, R J Knapp, V J Hruby, K C Rice, H Nagase, W R Roeske, H I Yamamura.   

Abstract

Intrinsic activities of different delta opioid agonists were determined in a [35S]GTPgammaS binding assay using cell membranes from Chinese hamster ovary (CHO) cells stably expressing the wild type (hDOR/CHO) or W284L mutant human delta opioid receptor (W284L/CHO). Agonist binding affinities were regulated more robustly by sodium and guanine nucleotide in W284L/CHO than in hDOR/ CHO cell membranes. The W284L mutation selectively reduced the affinity of SNC 80 while having moderate effect ((-) TAN 67) or no effect (DPDPE) on the affinities of other delta selective agonists. The mutation had opposite effects on the intrinsic activities of agonists belonging to different chemical classes. The effects of the mutation on agonist affinities and potencies were independent from its effects on the intrinsic activities of the agonists. Maximal stimulation of [35S]GTPgammaS binding by SNC 80 was 2-fold higher in W284L mutant cell membranes than in wild type hDOR/CHO cell membranes, despite lower receptor expression levels in the W284L/CHO cells. The binding affinity of SNC 80 however, was significantly reduced (15-fold and 30-fold in the absence or presence of sodium+GDP respectively) in W284L/CHO cell membranes relative to wild type hDOR/CHO membranes. Conversely, the Emax of (-)TAN 67 in the [35S]GTPgammaS binding assay was markedly reduced (0.6-fold of that of the wild type) with only a slight (6-fold) reduction in its binding affinity. The affinity and intrinsic activity of DPDPE on the other hand remained unchanged at the W284L mutant hDOR. The mutation had similar effects on the affinities potencies and intrinsic activities of (-)TAN 67 and SB 219825. The results indicate that delta opioid agonists of different chemical classes use specific conformations for G protein activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358332     DOI: 10.1016/s0024-3205(01)01011-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  4 in total

Review 1.  Design of peptide and peptidomimetic ligands with novel pharmacological activity profiles.

Authors:  Victor J Hruby; Minying Cai
Journal:  Annu Rev Pharmacol Toxicol       Date:  2013       Impact factor: 13.820

Review 2.  New paradigms and tools in drug design for pain and addiction.

Authors:  Victor J Hruby; Frank Porreca; Henry I Yamamura; Gordon Tollin; Richard S Agnes; Yeon Sun Lee; Minying Cai; Isabel Alves; Scott Cowell; Eva Varga; Peg Davis; Zdzislaw Salamon; William Roeske; Todd Vanderah; Josephine Lai
Journal:  AAPS J       Date:  2006-07-14       Impact factor: 4.009

Review 3.  Pharmacogenetics of new analgesics.

Authors:  Jörn Lötsch; Gerd Geisslinger
Journal:  Br J Pharmacol       Date:  2011-06       Impact factor: 8.739

4.  Modeling and simulation of the human delta opioid receptor.

Authors:  Mahalaxmi Aburi; Paul E Smith
Journal:  Protein Sci       Date:  2004-07-06       Impact factor: 6.725

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.